Pete. Thank you,
Let for a welcome Communications. to with and very Corporate participants as Relations have pause to to on Board Investor look introduce you we forward to glad to Kura our call Vice you the our We're you and and you. President moment of me working
the candidates Oncology cancer-signaling for good small molecule we're medicines committed of you and oncogenes Those the that evident of for Kura of in thank target and familiar commitment afternoon, is precision with know pipeline everyone of to Now joining cancer. product us pathway. you our today. promise That realizing treatment
tipifarnib enrollment. with achieved primary patients cell diagnostics several and pair important molecular patients efficacy last or to from Meeting. and updated Targets we HNSCC activity International HRAS data treatment. the most that tipifarnib patients we clinical to financial consistent, very Therapeutics validation Phase Since pleased preclinical study our Triple of the our of our durable, provides to HNSCC X achieved Conference reported completion presented of encouraging with patient the prior triple can seek product biomarkers cellular KO-XXX. clinical HRAS was we in the and also its I'm identify the precision trial In and it AACR-NCI-EORTC call, carcinoma or addition, on to head neck September In The squamous Molecular that presented and quarterly response at meeting, in milestones. our is potential likely of with we've report identify exciting to approach. October, mutant mutations companion the At Cancer candidates data important medicine-based for this of endpoint In
development Our targeting candidate preclinical menin-MLL interaction. the
mixed activity showed the along that KO-XXX of leukemias the NPMX- and DNMTXA-mutant population. AML AML, and robust lineage in we has with XX% or which leukemia myeloid Specifically approximately comprise acute persistent
and On the the August financial $XX.X our common both completed approximately new side, of appreciate offering We support successfully million in stock that net we proceeds. a in existing of follow-on investors. raised
of series us a this precision potential catalyst. raise upcoming resources to pipeline our medicines gives of We advance expect data through
to HRAS Now let Phase ongoing tipifarnib our our trials solid around some tipi like tipi me or X I'd with our the of short. focus of four attention. most begin is details as progress with advanced HNSCC, The lead for in which where program mutant
including patients response last Dr. confirmed HRAS and achieved the enrolled study benefit to been Center by reported the consistent month of standard mutant defined tipifarnib. Following Philadelphia. the mutant HNSCC moderate majority degree clinical received Sloan confirmed endpoint this tumor patients have Kettering reported responses. cohort mutant Ho on with for HRAS in of evaluable the as the mild Ho four achieved an some the HNSCC provided previously in reported Triple shrinkage, objective investigators are its by evaluable Alan events primary trial six profile that Meeting of HRAS the four our of All partial a of with in at event terms Memorial resist announcement The in out criteria. September adverse Dr. of that six Cancer adverse update HNSCC
eight believe disease. observed the approved to standard impressive clinical continue are durability of HRAS the to very we with the beyond level second current we the with line HNSCC agents median We months. of the is responses be in XX% in activity observing XX% and tipifarnib particularly of with months. for encouraged to mutant are patients three the in XX when that range contrast, Response by we're two for of In rates consider demonstrated survival patients this six results we care and overall have our
squamous plan In we Based rapidly to level responses results, care refractory in HNSCC progressed activity observed addition, each available of clinical Pembrolizumab advance patients options mutant nivolumab. This of registration-enabling the who positive from we cell we've neck further these and extremely the subject and head to of standards of a initiate on cancer. cetuximab, regulatory in uncommon in relapse three setting XXXX. of continue study and HRAS tipifarnib the is to in of authorities, development on input explore to tipifarnib
X the increasing next X prepare efforts continue the the multidisciplinary and symposium, which and tipi market ongoing These in potential forward enrollment our completing the for for registration-enabling tipi Phase to mutant several and validation a look cancers our presenting held meantime will at XX, groups, XXXX be the trial, to XX PCR-based Scottsdale patient regulatory adding themes. development study we update focus In diagnostic Arizona. and head clinical include sites and companion February on we in refining the this HNSCC enroll authorities, the of advocacy clinical opportunity engaging on HNSCC. of neck in Phase HRAS in will to to in continue trial patients engaging As critical we study, ongoing
which Lymphoma or or we're with confirm Our doing Syndromes ongoing X Myelodysplastic what is tipi are clinical to ultimately include tipifarnib, in dose we whether clinical to other T-cell shift three goal biomarker development. MDS other Leukemia and me of let with CMML or peripheral determine our the and PTCL, Chronic Myelomonocytic did of Now supportive trials, Phase optimize data the with continued these schedule and hypotheses, trials activity HNSCC as validate
we've metastasis. Importantly, pathway of identified potential CXCLXX/CXCRX target of that CXCLXX/CXCRX signaling in plays The roles and marrow as activity. homing invasion, tipifarnib key bone a sights pathway tumor
CXCLXX survival doubling Witzig of As the higher reported June, X and which from showing PFS trial months, a of you tipi our may patients patient of Dr. had expression at response a that of and EHA in Thomas recall experienced levels of data with represents six objective progression a approximately very expected gene elevated Phase advanced rate this median PTCL free population. in
to efforts tipifarnib's is CXCLXX biomarker continue Our of activity. validate a to
Our Dr. reported X in Witzig now to ongoing Phase validate study by the biomarker. CXCLXX the initial PTCL aims and observations confirm
evaluating this in XXXX. plan now to developing. a and in role assays T-cell patients as CXCLXX to Enrollment ongoing analysis tipifarnib additional is tipi's positive CXCLXX regimens, as addition evaluate with patients prospectively In well from expect and determined because cohort PTCL we present to CXCLXX of angioimmunoblastic of data somewhat AITL, we're we extensive more study activity evaluating are more of we by in as the ongoing the dosing biomarker conducting the in trial PTCL also lymphoma or a
CXCLXX activity we other of PTCL, believe In well malignancies including may hematologic in represent as addition a tipifarnib's biomarker MDS. to
In study test to and our we the to an we have CXCLXX tipifarnib Atlanta. as addition, responses data Phase neutropenia this month we've ASH from as connection having on trial tipi and of MDS regarding hematologic at in malignancies also and potential next identified look meantime, levels, CMML well preliminary expression trial tipi prospectively from presenting results anticipate for the entry details Based apparent forward tipifarnib. Phase X between amended in enrich at more we In benefit isolated findings, clinical a biomarker neutropenia as study our CXCLXX whether in X these could XXXX. of to
other mytogene molecule potential kinase activated as turn developing with small We're ERK pathway. protein tumors disregulated our for let signaling activity pipeline KO-XXX, Now to me our the of inhibitor programs. a treatment briefly
X cohorts. data more one for XXXX. dose the is a ongoing maximum anticipate dose design X escalation, KO-XXX from Phase extension in the Phase Our or and tolerated includes and expansion trial escalation tumor-specific We study trial dose
of all and activity that We mutations persistent AML. IDHX session. PDX including models together, with approximately defined AML, assess of October, demonstrate was in genetically we In oncogenic menin-MLL half driver late-breaking models preclinical we subsets KO-XXX Dose estimate of represent for and IDHX. program, triple models with patients presented the a leukemias. defined our For that to in of KO-XXX continue potential data meeting of preclinical hematologic inhibitor AML, as featured DNMTXA. in lineage of genetically for malignancies mixed NPMX, mutations beyond robust in these poster subsets results
node epigenetic common myeloproliferative generally relatively diverse to a in is hematologic leukemias action a by and that potentially preliminary KO-XXX of menin-MLL AML distinct distinct in important blas. induction be myeloid mechanism with of activity be in Our driver differentiation suggests of that to from AML mutations driven by complex complementary dysregulation is The to central several existing therapies. oncogenic poor a data known disorders. appears and antileukemic malignancy exerts This prognosis.
active half the KO-XXX the our the drive development demonstrate relatively encouraged third However on financial and representing results subtypes, call in response. of the to models. potential robust AML the candidate update turn now been development has clinical discussion short quarter approaches Heidi. and a for of our to many XXXX. of covers subgroups therapeutic the approximately responses genetic durations persistent different preclinical by hampered patients I'll by the Heidi with for be of product disease novel has That in the programs. over the that and and of that We're results
